These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35878189)

  • 41. Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin.
    Suppa A; Asci F; Saggio G; Marsili L; Casali D; Zarezadeh Z; Ruoppolo G; Berardelli A; Costantini G
    Parkinsonism Relat Disord; 2020 Apr; 73():23-30. PubMed ID: 32222482
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors Associated with Failure of Botulinum Toxin Injection in Adductor Spasmodic Dysphonia.
    Zhao K; Guillaud M; Hu A
    Ann Otol Rhinol Laryngol; 2020 Oct; 129(10):996-1002. PubMed ID: 32468829
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of spasmodic dysphonia with botulinum toxin].
    Klap P; Marion MH; Perrin A; Fresnel-Elbaz E
    Ann Otolaryngol Chir Cervicofac; 1991; 108(8):477-82; discussion 482-3. PubMed ID: 1789624
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Surgical treatment for adductor spasmodic dysphonia--efficacy of bilateral thyroarytenoid myectomy under microlaryngoscopy.
    Nakamura K; Muta H; Watanabe Y; Mochizuki R; Yoshida T; Suzuki M
    Acta Otolaryngol; 2008; 128(12):1348-53. PubMed ID: 18607929
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes.
    Novakovic D; Waters HH; D'Elia JB; Blitzer A
    Laryngoscope; 2011 Mar; 121(3):606-12. PubMed ID: 21298641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alternating Unilateral Versus Bilateral Injections of Botulinum Toxin for the Treatment of Adductor Spasmodic Dysphonia.
    Lee SJ; Kang MS; Choi HS; Lim JY
    Otolaryngol Head Neck Surg; 2021 Apr; 164(4):815-820. PubMed ID: 32957836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abductor paralysis after botox injection for adductor spasmodic dysphonia.
    Venkatesan NN; Johns MM; Hapner ER; DelGaudio JM
    Laryngoscope; 2010 Jun; 120(6):1177-80. PubMed ID: 20513036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage.
    Marchese MR; D'Alatri L; Bentivoglio AR; Paludetti G
    Toxicon; 2018 Dec; 155():38-42. PubMed ID: 30315835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Botulinum toxin injection for treatment of spasmodic dysphonia: experience at Srinagarind Hospital.
    Srirompotong S; Saeseow P; Taweesaengsuksakul R; Kharmwan S; Srirompotong S
    J Med Assoc Thai; 2006 Dec; 89(12):2077-80. PubMed ID: 17214059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analgesia in Transcutaneous Laryngeal Botulinum Toxin Injections: A Randomized Crossover Trial.
    Heyes R; Adler CH; Yee C; Lott DG; Karle WE
    Laryngoscope; 2024 May; 134(5):2277-2281. PubMed ID: 38157199
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
    Meyer TK; Hu A; Hillel AD
    Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
    Kendall KA; Leonard RJ
    J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
    Shoffel-Havakuk H; Marks KL; Morton M; Johns MM; Hapner ER
    Laryngoscope; 2019 Feb; 129(2):448-453. PubMed ID: 30315575
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spasmodic dysphonia: let's look at that again.
    Murry T
    J Voice; 2014 Nov; 28(6):694-9. PubMed ID: 24972536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients-an Australian experience.
    Tisch SH; Brake HM; Law M; Cole IE; Darveniza P
    J Clin Neurosci; 2003 Jul; 10(4):434-8. PubMed ID: 12852881
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient Experience Contributing to Outcomes of Laryngeal Botulinum Toxin Injection.
    Rutt A; Kennelly KD; Martinez-Paredes JF
    J Voice; 2022 Mar; 36(2):272-276. PubMed ID: 32553551
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Spasmodic dysphonia follow-up with videolaryngoscopy and voice spectrography during treatment with botulinum toxin.
    Esposito M; Dubbioso R; Apisa P; Allocca R; Santoro L; Cesari U
    Neurol Sci; 2015 Sep; 36(9):1679-82. PubMed ID: 25966878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
    Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
    J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Practice Patterns and Barriers in Botulinum Toxin Injection for the Treatment of Voice Disorders.
    McGarey PO; Simpson CB; Daniero JJ
    J Voice; 2022 Jan; 36(1):113-118. PubMed ID: 32467003
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of Laryngeal Botulinum Neurotoxin Injection With Work Productivity for Patients With Spasmodic Dysphonia.
    Meyer TK; Spiekerman C; Kaye R; Blitzer A; Kamizi RS; Jiang L; Weaver EM
    JAMA Otolaryngol Head Neck Surg; 2021 Sep; 147(9):804-810. PubMed ID: 34351425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.